NASDAQ:SNDX Syndax Pharmaceuticals (SNDX) Stock Forecast, Price & News $16.26 -0.05 (-0.31%) (As of 09/21/2023 ET) Add Compare Share Share Today's Range$16.07▼$16.5050-Day Range$16.26▼$21.7752-Week Range$16.07▼$29.86Volume789,744 shsAverage Volume824,571 shsMarket Capitalization$1.13 billionP/E RatioN/ADividend YieldN/APrice Target$36.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Syndax Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside121.4% Upside$36.00 Price TargetShort InterestBearish10.02% of Shares Sold ShortDividend StrengthN/ASustainability-1.12Upright™ Environmental ScoreNews Sentiment0.58Based on 2 Articles This WeekInsider TradingSelling Shares$3.74 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.94) to ($2.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.40 out of 5 starsMedical Sector230th out of 965 stocksPharmaceutical Preparations Industry92nd out of 445 stocks 4.5 Analyst's Opinion Consensus RatingSyndax Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $36.00, Syndax Pharmaceuticals has a forecasted upside of 121.4% from its current price of $16.26.Amount of Analyst CoverageSyndax Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted10.02% of the outstanding shares of Syndax Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverSyndax Pharmaceuticals has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Syndax Pharmaceuticals has recently decreased by 2.79%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSyndax Pharmaceuticals does not currently pay a dividend.Dividend GrowthSyndax Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSyndax Pharmaceuticals has received a 66.26% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Syndax Pharmaceuticals is -1.12. Previous Next 2.0 News and Social Media Coverage News SentimentSyndax Pharmaceuticals has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Syndax Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest5 people have searched for SNDX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Syndax Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Syndax Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,742,083.00 in company stock.Percentage Held by InsidersOnly 4.70% of the stock of Syndax Pharmaceuticals is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Syndax Pharmaceuticals are expected to grow in the coming year, from ($2.94) to ($2.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Syndax Pharmaceuticals is -6.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syndax Pharmaceuticals is -6.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyndax Pharmaceuticals has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Syndax Pharmaceuticals (NASDAQ:SNDX) StockSyndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 for the treatment of KMT2A rearranged (KMT2Ar) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Read More SNDX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNDX Stock News HeadlinesSeptember 20, 2023 | benzinga.comLooking At Syndax Pharmaceuticals's Recent Unusual Options ActivitySeptember 13, 2023 | americanbankingnews.comTraders Purchase High Volume of Put Options on Syndax Pharmaceuticals (NASDAQ:SNDX)September 22, 2023 | Edge On The Street (Ad)The Strategic Gold Play You Haven't Heard AboutExperts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure. September 8, 2023 | seekingalpha.comSyndax Pharmaceuticals: Positive Axatilimab Phase 2 ResultsAugust 31, 2023 | finance.yahoo.comSyndax Announces Participation at the Citi 18th Annual BioPharma ConferenceAugust 16, 2023 | msn.comJP Morgan Maintains Syndax Pharmaceuticals (SNDX) Overweight RecommendationAugust 8, 2023 | markets.businessinsider.comSyndax Pharmaceuticals (SNDX) Gets a Buy from Robert W. BairdAugust 4, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Syndax Pharmaceuticals (SNDX)September 22, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."August 3, 2023 | finance.yahoo.comSyndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business UpdateAugust 2, 2023 | msn.comSyndax Pharmaceuticals (SNDX) Price Target Increased by 8.43% to 37.29July 28, 2023 | msn.comScotiabank Initiates Coverage of Syndax Pharmaceuticals (SNDX) with Sector Outperform RecommendationJuly 27, 2023 | markets.businessinsider.comWhat 7 Analyst Ratings Have To Say About Syndax PharmaceuticalsJuly 27, 2023 | msn.comBarclays Maintains Syndax Pharmaceuticals (SNDX) Overweight RecommendationJuly 25, 2023 | finance.yahoo.comSyndax to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 3, 2023July 24, 2023 | msn.comHC Wainwright & Co. Reiterates Syndax Pharmaceuticals (SNDX) Buy RecommendationJuly 24, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Syndax Pharmaceuticals (SNDX)July 24, 2023 | finance.yahoo.comSyndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host DiseaseJuly 11, 2023 | markets.businessinsider.comSyndax Pharmaceuticals Set for Potential Breakthrough with Revumenib: Analyst Calls It 'Potentially Best-In-Class' In Competitive LandscapeJuly 11, 2023 | msn.comGuggenheim Initiates Coverage of Syndax Pharmaceuticals (SNDX) with Buy RecommendationJune 30, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Accolade (ACCD)June 27, 2023 | msn.comBTIG Maintains Syndax Pharmaceuticals (SNDX) Buy RecommendationJune 26, 2023 | benzinga.comBTIG Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $35June 26, 2023 | markets.businessinsider.comBTIG Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX)June 8, 2023 | seekingalpha.comSyndax Pharmaceuticals: Precision Oncology Leveraging Strong Financials And R&DMay 23, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Premier (PINC)May 12, 2023 | msn.comCitigroup Maintains Syndax Pharmaceuticals (SNDX) Buy RecommendationSee More Headlines Receive SNDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SNDX Company Calendar Last Earnings8/03/2023Today9/22/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SNDX CUSIPN/A CIK1395937 Webwww.syndax.com Phone(781) 419-1400Fax781-419-1420Employees107Year FoundedN/APrice Target and Rating Average Stock Price Forecast$36.00 High Stock Price Forecast$42.00 Low Stock Price Forecast$33.00 Forecasted Upside/Downside+121.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-149,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-39.08% Return on Assets-36.69% Debt Debt-to-Equity RatioN/A Current Ratio13.56 Quick Ratio13.56 Sales & Book Value Annual Sales$139.71 million Price / Sales8.09 Cash FlowN/A Price / Cash FlowN/A Book Value$7.76 per share Price / Book2.10Miscellaneous Outstanding Shares69,480,000Free Float66,218,000Market Cap$1.13 billion OptionableOptionable Beta1.13 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Michael A. Metzger M.B.A. (Age 52)CEO & Director Comp: $1.05MMr. Keith Alan Goldan CPA (Age 52)CFO, Treasurer & Chief Accounting Officer Comp: $649.07kMr. Luke J. Albrecht (Age 43)Sr. VP, Gen. Counsel & Sec. Comp: $605.82kDr. Catherine Madigan M.D. (Age 51)Chief Medical Officer Comp: $764.41kMr. Steve M. Sabus (Age 57)Chief Commercial Officer Comp: $523.44kDr. Peter Ordentlich B.Sc. (Age 54)Ph.D., Co-Founder & Chief Scientific Officer Dr. Richard A. Heyman Ph.D. (Age 66)Co-Founder Dr. Ronald M. Evans Ph.D.Co-Founder, Advisor and Chair of Scientific Advisory BoardDr. Michael Downes Ph.D.Co-FounderSharon KlahreVP of Investor Relations & CommunicationsMore ExecutivesKey CompetitorsMirum PharmaceuticalsNASDAQ:MIRMDisc Medicine OpcoNASDAQ:IRONRevance TherapeuticsNASDAQ:RVNCDay One BiopharmaceuticalsNASDAQ:DAWNSage TherapeuticsNASDAQ:SAGEView All CompetitorsInsiders & InstitutionsBarclays PLCSold 812,691 shares on 9/21/2023Ownership: 0.244%California State Teachers Retirement SystemBought 648 shares on 8/21/2023Ownership: 0.101%Nuveen Asset Management LLCBought 9,710 shares on 8/16/2023Ownership: 0.232%Bayesian Capital Management LPSold 995 shares on 8/15/2023Ownership: 0.025%Royal Bank of CanadaBought 1,202 shares on 8/15/2023Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions SNDX Stock - Frequently Asked Questions Should I buy or sell Syndax Pharmaceuticals stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SNDX shares. View SNDX analyst ratings or view top-rated stocks. What is Syndax Pharmaceuticals' stock price forecast for 2023? 9 Wall Street research analysts have issued 1-year price targets for Syndax Pharmaceuticals' shares. Their SNDX share price forecasts range from $33.00 to $42.00. On average, they anticipate the company's stock price to reach $36.00 in the next year. This suggests a possible upside of 121.4% from the stock's current price. View analysts price targets for SNDX or view top-rated stocks among Wall Street analysts. How have SNDX shares performed in 2023? Syndax Pharmaceuticals' stock was trading at $25.45 at the beginning of 2023. Since then, SNDX stock has decreased by 36.1% and is now trading at $16.26. View the best growth stocks for 2023 here. When is Syndax Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our SNDX earnings forecast. How were Syndax Pharmaceuticals' earnings last quarter? Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) posted its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.09. During the same quarter in the previous year, the firm posted ($0.62) EPS. What ETFs hold Syndax Pharmaceuticals' stock? ETFs with the largest weight of Syndax Pharmaceuticals (NASDAQ:SNDX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), ALPS Medical Breakthroughs ETF (SBIO) and SPDR S&P Biotech ETF (XBI).Simplify Health Care ETF (PINK). What other stocks do shareholders of Syndax Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU). When did Syndax Pharmaceuticals IPO? (SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers. What is Syndax Pharmaceuticals' stock symbol? Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX." Who are Syndax Pharmaceuticals' major shareholders? Syndax Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.18%), State Street Corp (5.98%), Kynam Capital Management LP (4.69%), Jennison Associates LLC (3.66%), Geode Capital Management LLC (1.90%) and Point72 Asset Management L.P. (1.78%). Insiders that own company stock include Alexander Nolte, Briggs Morrison, Dennis Podlesak, Fabrice Egros, Keith A Goldan, Keith Katkin, Michael A Metzger, Michael L Meyers, Peter Ordentlich, Pierre Legault and William Meury. View institutional ownership trends. How do I buy shares of Syndax Pharmaceuticals? Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Syndax Pharmaceuticals' stock price today? One share of SNDX stock can currently be purchased for approximately $16.26. How much money does Syndax Pharmaceuticals make? Syndax Pharmaceuticals (NASDAQ:SNDX) has a market capitalization of $1.13 billion and generates $139.71 million in revenue each year. The company earns $-149,340,000.00 in net income (profit) each year or ($2.43) on an earnings per share basis. How many employees does Syndax Pharmaceuticals have? The company employs 107 workers across the globe. How can I contact Syndax Pharmaceuticals? Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The official website for the company is www.syndax.com. The company can be reached via phone at (781) 419-1400, via email at ir@syndax.com, or via fax at 781-419-1420. This page (NASDAQ:SNDX) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.